Search Results
315 Results Found for “metastatic breast cancer”
Metastatic triple-negative breast cancer (mTNBC) is a clinically heterogeneous disease, but compared with other breast cancer subtypes, triple-negative breast cancer (TNBC) is generally associated with a poorer prognosis and has historically had limited therapeutic options.1 The 5-year survival rate remains ...
Choosing the appropriate adjuvant therapy in patients with melanoma undergoing neoadjuvant treatment
This article examines current evidence supporting the use of neoadjuvant immunotherapy in patients with resectable macroscopic stage III melanoma and critically discusses the selection of appropriate adjuvant therapy following surgery. It is written in the context of emerging evidence from ...
Circulating tumor DNA (ctDNA) has emerged as an innovative and minimally invasive tool in precision oncology. With a short half-life of 30–120 min, ctDNA provides real-time insight into tumor dynamics.1 In early-stage breast cancer, there is growing evidence supporting its potential ...
Join us as leading experts discuss key data from the Plenary, Late-breaking and top oral sessions across each major disease area at ASCO 2026 touchONCOLOGY coverage of ASCO 2026 2026 American Society of Clinical Oncology (ASCO) Annual Meeting brought together the global oncology ...
New ASCENT-04 data presented at ASCO 2026 suggest that first-line sacituzumab govitecan plus pembrolizumab may provide sustained clinical benefit beyond first progression in patients with previously untreated PD-L1-positive metastatic triple-negative breast cancer. The exploratory post-hoc analysis showed improved PFS2 versus chemotherapy plus pembrolizumab, despite high crossover to sacituzumab govitecan in the control arm.
Dr Rupert Bartsch (University of Vienna, Austria) highlighted six important studies across the breast cancer landscape presented at ASCO 2026. The studies below discuss interesting and strategic developments in genomic risk stratification in early disease, supportive care optimization, HER2-positive metastatic strategies and novel antibody–drug conjugates in triple-negative breast cancer.
Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related mortality worldwide.1 Over the past two decades, the molecular characterization of NSCLC has transformed the therapeutic landscape by enabling the development of targeted therapies that have significantly improved outcomes ...
Small bowel adenocarcinoma (SBA) is a rare gastrointestinal malignancy, accounting for about 1–3% of gastrointestinal cancers.1,2 Its reported incidence has increased in recent decades, likely reflecting improved detection by balloon-assisted and capsule endoscopy and the more widespread use of cross-sectional imaging.3,4 ...
Pancreatic cancer (PC) is the tenth most common cancer in 2024, with 66,440 new cases and 51,570 deaths.1,2 Globally, the prevalence varies from 10/100,000 cases in the Americas and Europe to 0.9/100,000 cases in South Central Asia and most of Africa.3 Currently, it has the ...
As we begin 2026, Dr Ana Tecic Vuger (University Hospital for Tumors, Zagreb, Croatia) reflects on the major breakthroughs throughout 2025. The breast cancer community has witnessed transformative progress across the continuum of research and clinical care, from more precise targeted therapies and novel endocrine strategies to advances in biomarker-driven treatment sequencing and survivorship. The major oncology meetings – ASCO 2025, ESMO/ESMO Breast 2025, and the San Antonio Breast Cancer Symposium (SABCS) 2025 – offered a rich tapestry of data that helps shape practice and sharpen research priorities.
Breakthroughs from the 2025 San Antonio Breast Cancer Symposium in oral SERDs, HER2-targeted maintenance therapy, ADCs and next-generation endocrine combinations are reshaping breast cancer care across early and metastatic disease. From practice-changing phase III data to nuanced treatment selection in triple-positive and ESR1-mutant disease, this in-depth report unpacks what the latest trials really mean for clinicians. Register now to read the full analysis and stay ahead of rapidly evolving practice.
2025 has brought exciting developments in oncology, with groundbreaking research and real-world progress showcased at ASCO, ESMO, EHA, ASH and many more leading conferences around the world. We asked our key faculty to share what they believe has been most impactful so far this year – here’s what they told us.
The European Society for Medical Oncology (ESMO) 2025 congress brought over 100 late-breaking abstracts, 250 sessions, 600 expert speakers and 33,800 delegates to Berlin in October. The meeting highlighted innovations ranging from novel agents to real-world evidence and patient-centred care. In this article, hear from the experts on the key breakthroughs and clinical insights set to shape the future of oncology practice.
In this interview, we speak with Prof. Domenica Lorusso (Humanitas Hospital San Pio X, Humanitas University, Rozzano, Milan) about the latest ROSELLA findings, their implications for clinical practice, the next steps in this research and other key data presented at this year’s meeting.
At ESMO25, Professor John Crown shared insights into the five-year NATALEE trial data, revealing a sustained invasive disease-free survival advantage with adjuvant ribociclib + NSAI in HR+/HER2− early breast cancer. With benefits extending even after treatment completion, the findings could reshape adjuvant strategies for high-risk patients.
“ESMO 2025 felt like a true turning point in breast cancer care” At the European Society for Medical Oncology (ESMO) 2025 congress, the landscape of early and advanced breast cancer management was powerfully reshaped, with new data spanning hormone-receptor positive (HR+), human ...
Cervical cancer (CC) is the fourth most common cancer among women worldwide, with an estimated 604,000 new cases and 342,000 CC-related deaths in 2020.1# Approximately 90% of CCs are caused by infection with human papillomavirus (HPV).2 Even though the adoption of both primary (HPV ...
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
